U.S. markets open in 8 hours 31 minutes

AnaptysBio, Inc. (AN6.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
17.60-0.80 (-4.35%)
At close: 7:55PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close18.40
Bid0.00 x 0
Ask0.00 x 0
Day's Range17.40 - 18.30
52 Week Range11.88 - 29.09
Avg. Volume9
Market Cap496.595M
Beta (5Y Monthly)0.05
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher
      Simply Wall St.

      Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

      Celebrations may be in order for AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders, with the analysts delivering a...

    • Why AnaptysBio Stock Is Attractive After 30% Selloff

      Why AnaptysBio Stock Is Attractive After 30% Selloff

      AnaptysBio Inc’s (NASDAQ: ANAB) stock seems attractive after the POPLAR data and the 30% selloff, while there are several catalysts over the next 12-18 months, according to Truist Securities. AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients, according to its website. The AnaptysBio Analyst: Joon Lee upgraded the rating for AnaptysBio from Hold to Buy, while raising the price target from $27 to $34. The AnaptysBio Thesis: The company is posed for value creation in 2021 and 2022, given the “rich pipeline from wholly-owned and partnered programs,” Lee said in the upgrade note. “Our due diligence suggest imsidolimab may have stronger rationale for EGFRi mediated skin toxicity with interim topline expected YE21. And GPP, for which ANAB is planning to start Ph3 mid-2021, may be a much larger indication than we currently model,” he wrote. “Also, we like the rich pipeline, including ANB030, a PD-1 agonist (LLY also has one) and ANB032, a BLTA modulator. Lastly, we raise ANAB floor based on updated milestone expectations from GSK collab,” the analyst said. ANAB Price Action: Shares of AnaptysBio had risen by 2.95% to $20.40 at the time of publication Tuesday. (Photo by Bill Oxford on Unsplash) Latest Ratings for ANAB DateFirmActionFromTo Mar 2021Truist SecuritiesUpgradesHoldBuy Mar 2021WedbushDowngradesOutperformNeutral Feb 2021JP MorganUpgradesUnderweightOverweight View More Analyst Ratings for ANAB View the Latest Analyst Ratings See more from BenzingaClick here for options trades from BenzingaWhy Advanced Micro Devices's EPYC3 Server Launch Impressed This AnalystHere's Why BofA Raised US Steel Target By 50%© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Why AnaptysBio Stock Is Popping Today
      Motley Fool

      Why AnaptysBio Stock Is Popping Today

      Shares of clinical-stage biotech AnaptysBio (NASDAQ: ANAB) were rising sharply on Tuesday following bullish commentary from a Wall Street analyst. The company's stock was up by 5.6% as of 12:58 p.m. EDT, after rising by as much as 12% earlier in the day. Truist analyst Joon Lee upgraded AnaptysBio stock to buy from hold.